Puesta al dı́a : Enfermedades sistémicas y corazón ( VI ) Enfermedades hematológicas : desde dentro del corazón

The fundamental relationship between blood disorders and the cardiovascular system originates within multiple points of interface, ranging from the heart and its structural constituents to include heart chambers, valves, coronary arteries, coronary veins, and the cerebrovascular and peripheral vasculature. While the cellular components of circulating blood derive their primary origin from multipotent progenitor cells, plasma-based components, which include coagulation proteins, are mostly born of hepatic synthesis and endothelial cells. Here we provide a focused overview of nononcological blood disorders and their potential impact on the arterial circulatory system as common phenotypes, including myocardial infarction, ischemic stroke and peripheral arterial occlusive events. Venous thromboembolism is employed in our discussion as a clinical template. We also provide practical steps and guidance for diagnostic testing and management in routine clinical practice. Full English text available from: www.revespcardiol.org 2011 Sociedad Española de Cardiologı́a. Published by Elsevier España, S.L. All rights reserved.

[1]  S. Vesely,et al.  Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic‐uremic syndromes , 2010, American journal of hematology.

[2]  P. Swerdlow,et al.  Beneficial effects of nitric oxide breathing in adult patients with sickle cell crisis , 2010, American journal of hematology.

[3]  C. Legnani,et al.  No early signs of atherosclerotic alterations in carriers of inherited thrombophilia. , 2010, European journal of internal medicine.

[4]  K. Ataga,et al.  The risks and benefits of long‐term use of hydroxyurea in sickle cell anemia: A 17.5 year follow‐up , 2010, American journal of hematology.

[5]  K. Alexander,et al.  Incidence, Correlates, and Outcomes of Acute, Hospital-Acquired Anemia in Patients With Acute Myocardial Infarction , 2010, Circulation. Cardiovascular quality and outcomes.

[6]  G. Stone,et al.  Impact of anemia on clinical outcomes of patients with ST-segment elevation myocardial infarction in relation to gender and adjunctive antithrombotic therapy (from the HORIZONS-AMI trial). , 2010, The American journal of cardiology.

[7]  K. Hassell.  Population estimates of sickle cell disease in the U.S. , 2010, American journal of preventive medicine.

[8]  W. Aronow,et al.  Cardiovascular Manifestations in Patients With Thrombotic Thrombocytopenic Purpura: A Single‐center Experience , 2010, Clinical cardiology.

[9]  G. Raskob,et al.  Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop. , 2010, American Journal of Preventive Medicine.

[10]  S. Vesely,et al.  The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports , 2010, American journal of hematology/oncology.

[11]  Michael R. Waldrum,et al.  Platelet count and prothrombin time help distinguish thrombotic thrombocytopenic purpura-hemolytic uremic syndrome from disseminated intravascular coagulation in adults. , 2010, American journal of clinical pathology.

[12]  A. Neskovic,et al.  Primary PCI for Acute Myocardial Infarction in a Patient with Idiopathic Thrombocytopenic Purpura , 2010, Herz.

[13]  H. Tsai.  Pathophysiology of thrombotic thrombocytopenic purpura , 2010, International journal of hematology.

[14]  J. Kiss.  Thrombotic thrombocytopenic purpura: recognition and management , 2010, International journal of hematology.

[15]  P. Giordano,et al.  Management of Chronic Childhood Immune Thrombocytopenic Purpura: AIEOP Consensus Guidelines , 2009, Acta Haematologica.

[16]  Matthew Mort,et al.  The Human Gene Mutation Database: providing a comprehensive central mutation database for molecular diagnostics and personalised genomics , 2009, Human Genomics.

[17]  M. Telen,et al.  Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease , 2009, American journal of hematology.

[18]  S. Solomon,et al.  Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED‐HF): a Phase III, anaemia correction, morbidity–mortality trial , 2009, European journal of heart failure.

[19]  M. Marques.  Thrombotic thrombocytopenic purpura and heparin-induced thrombocytopenia: two unique causes of life-threatening thrombocytopenia. , 2009, Clinics in laboratory medicine.

[20]  E. V. Van Cott,et al.  Laboratory evaluation of hypercoagulability. , 2009, Clinics in laboratory medicine.

[21]  J. Kelton,et al.  Studies of the immune response in heparin-induced thrombocytopenia. , 2009, Blood.

[22]  S. Vesely,et al.  Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura , 2009, Transfusion.

[23]  J. Thachil.  Nitric oxide in immune thrombocytopenic purpura , 2009, Hematology.

[24]  D. Kaul,et al.  Sickle Red Cell–Endothelium Interactions , 2009, Microcirculation.

[25]  L. Kuller,et al.  Poor 1-Year Outcomes After Percutaneous Coronary Interventions in Systemic Lupus Erythematosus: Report From the National Heart, Lung, and Blood Institute Dynamic Registry , 2008, Circulation. Cardiovascular interventions.

[26]  M. Gladwin,et al.  Pulmonary complications of sickle cell disease. , 2008, The New England journal of medicine.

[27]  B. Mahmoodi,et al.  Hereditary Deficiency of Protein C or Protein S Confers Increased Risk of Arterial Thromboembolic Events at a Young Age: Results From a Large Family Cohort Study , 2008, Circulation.

[28]  P. Monagle,et al.  Impact of Inherited Thrombophilia on Venous Thromboembolism in Children: A Systematic Review and Meta-Analysis of Observational Studies , 2008, Circulation.

[29]  Ian Mackie,et al.  Regional UK TTP Registry: correlation with laboratory ADAMTS 13 analysis and clinical features , 2008, British journal of haematology.

[30]  I. Anand.  Anemia and chronic heart failure implications and treatment options. , 2008, Journal of the American College of Cardiology.

[31]  J. Hirsh,et al.  Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[32]  N. J. Robinson,et al.  Prevalence of diagnosed chronic immune thrombocytopenic purpura in the US: analysis of a large US claim database: a rebuttal , 2008, Journal of thrombosis and haemostasis : JTH.

[33]  S. Katz,et al.  The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes , 2008, Heart Failure Reviews.

[34]  Brian R. Long,et al.  The role of antiphospholipid syndrome in cardiovascular disease. , 2008, Hematology/oncology clinics of North America.

[35]  P. Armstrong,et al.  Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and Anemia , 2008, Circulation.

[36]  Paolo Prandoni,et al.  The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. , 2007, Haematologica.

[37]  R. Levine,et al.  How frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia? , 2006, Chest.

[38]  C. Parikh,et al.  HEMATOLOGY: ISSUES IN THE DIALYSIS PATIENT: When Heparin Causes Thrombosis: Significance, Recognition, and Management of Heparin‐Induced Thrombocytopenia in Dialysis Patients , 2006, Seminars in dialysis.

[39]  G. Hankey,et al.  Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. , 2006, Archives of internal medicine.

[40]  W. Ageno,et al.  Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis. , 2006, Blood.

[41]  J. Eikelboom,et al.  Management of antiphospholipid antibody syndrome: a systematic review. , 2006, JAMA.

[42]  M. Gladwin,et al.  Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension , 2005, British journal of haematology.

[43]  V. Ganesan,et al.  Thrombophilia and first arterial ischaemic stroke: a systematic review , 2005, Archives of Disease in Childhood.

[44]  Sunil V. Rao,et al.  Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. , 2004, JAMA.

[45]  D. Girelli,et al.  Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations. , 2004, Blood.

[46]  P. Gorelick,et al.  Clopidogrel-Associated TTP: An Update of Pharmacovigilance Efforts Conducted by Independent Researchers, Pharmaceutical Suppliers, and the Food and Drug Administration , 2004, Stroke.

[47]  T. Barbui,et al.  Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. , 2003, Blood.

[48]  B. Dahlbäck,et al.  Functional characterization of recombinant FV Hong Kong and FV Cambridge. , 2002, Blood.

[49]  U. Seligsohn,et al.  Genetic susceptibility to venous thrombosis. , 2001, The New England journal of medicine.

[50]  P. Reitsma,et al.  Geographic Distribution of the 20210 G to A Prothrombin Variant , 1998, Thrombosis and Haemostasis.

[51]  N. Dzimiri,et al.  World distribution of factor V Leiden , 1996, The Lancet.

[52]  P. Ridker,et al.  Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. , 1995, The New England journal of medicine.

[53]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[54]  P. Wells,et al.  Prevalence of antithrombin deficiency in healthy blood donors: A cross‐sectional study , 1994, American journal of hematology.

[55]  P. Reitsma,et al.  Citations from the Literature , 2003 .

[56]  R. Garrick.  A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease , 2010 .

[57]  L. Haywood.  Cardiovascular function and dysfunction in sickle cell anemia. , 2009, Journal of the National Medical Association.

[58]  J. Brouwer.  Clinical implications of deficiencies of protein S, protein C or antithrombin , 2009 .

[59]  M. Anastasiou-Nana,et al.  Anemia in heart failure: pathophysiologic insights and treatment options. , 2009, Future cardiology.

[60]  J. Kelton,et al.  New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses. , 2009, Expert opinion on investigational drugs.

[61]  M. Aiach,et al.  Thirty-three Novel Mutations in the Protein C Gene , 2000, Thrombosis and Haemostasis.

[62]  F. Bernardi,et al.  Scientific and Standardization Committee Communication Protein S Deficiency: A Database of Mutations - FIRST UPDATE For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis , 2000 .

[63]  B. Dahlbäck.  The protein C anticoagulant system: inherited defects as basis for venous thrombosis. , 1995, Thrombosis research.